Chembio Diagnostics, Inc.
CEMI · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.03 | 0.03 | 0.02 |
| FCF Yield | -52.50% | -46.34% | -6.53% | -18.87% |
| EV / EBITDA | 8.12 | -3.19 | -4.09 | -2.67 |
| Quality | ||||
| ROIC | -7.88% | -13.76% | -13.52% | -15.38% |
| Gross Margin | 38.78% | 13.76% | 11.73% | 19.09% |
| Cash Conversion Ratio | 3.31 | 0.76 | 0.06 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.65% | 25.05% | 24.70% | 15.11% |
| Free Cash Flow Growth | 48.15% | -321.62% | 72.46% | 35.09% |
| Safety | ||||
| Net Debt / EBITDA | 4.58 | -0.91 | -0.58 | -0.14 |
| Interest Coverage | -3.10 | 0.00 | -8.54 | -10.97 |
| Efficiency | ||||
| Inventory Turnover | 0.73 | 1.14 | 0.72 | 1.29 |
| Cash Conversion Cycle | 254.08 | 92.52 | 125.64 | 84.04 |